Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer

Atul Batra, Rodrigo Rigo, Dropen Sheka, Winson Y Cheung

ORCID number: Atul Batra (0000-0002-1934-8408); Rodrigo Rigo (0000-0002-4188-0329); Dropen Sheka (0000-0002-7050-0794); Winson Y Cheung (0000-0002-3679-4290).

Author contributions: Batra A, Rigo R, Sheka D and Cheung WY collected the data and wrote the paper.

Conflict-of-interest statement: Authors declare no conflict of interests for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Received: February 24, 2020  Peer-review started: February 24, 2020  First decision: April 9, 2020  Revised: May 8, 2020  Accepted: May 29, 2020  Article in press: May 29, 2020  Published online: June 15, 2020

Abstract

Colon cancer represents one of the most common cancers diagnosed in older adults worldwide. The standard of care in resected stage II and stage III colon cancer continues to evolve. While there is unequivocal evidence to suggest both disease free and overall survival benefits with the use of combination chemotherapy in patients with stage III colon cancer, data regarding its use in patients with stage II colon cancer are less clear. Further, although colon cancer is a disease that affects older adults, there is considerable debate on the value of adjuvant chemotherapy in the aging population. In particular, many older patients are undertreated when compared to their younger counterparts. In this review, we will describe the clinical trials that contributed to the current adjuvant chemotherapy approach in colon cancer, discuss representation of older adults in trials and the specific challenges associated with the management of this subpopulation, and highlight the role of comprehensive geriatric assessments. We will also review how real-world evidence complements the data gaps from clinical trials of early stage colon cancer.

Key words: Colon cancer; Older adults; Adjuvant chemotherapy; Real-world evidence

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Use of adjuvant chemotherapy consisting of fluoropyrimidines with/without oxaliplatin has improved survival outcomes for patients with resected colon cancer, especially in those with stage III disease. However, older adults are often not given the opportunity to benefit from chemotherapy after surgery because undertreatment may occur due to various patient and physician related factors. The issue is further compounded by the limited representation of older adults in clinical trials, resulting in underpowered subgroup analyses that do not provide conclusive answers regarding the
utility of adjuvant chemotherapy in the advanced age group. We herein review the role of adjuvant chemotherapy in early stage colon cancer, specifically in the context of the older subpopulation, by focusing on both data from clinical trials and data from real-world evidence sources.

Citation: Batra A, Rigo R, Sheka D, Cheung WY. Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer. *World J Gastrointest Oncol* 2020; 12(6): 604-618
URL: https://www.wjgnet.com/1948-5204/full/v12/i6/604.htm
DOI: https://dx.doi.org/10.4251/wjgo.v12.i6.604

INTRODUCTION
Colon cancer is the fourth most frequently diagnosed cancer in the world, with approximately 1.1 million new cases diagnosed annually[1]. The median age at diagnosis is 67 years, making it the third most common cancer diagnosis in older patients[2,3].

The definitive treatment for localized colon cancer is surgery, whereby the risk of recurrence increases as the local extent of disease increases[3]. Adjuvant chemotherapy is targeted at occult metastasis and it is recommended in stage II disease with high-risk features, and stage III colon cancer[4-6]. Available treatment options include single agent fluoropyrimidine (5-FU or capecitabine) and combination chemotherapy consisting of a fluoropyrimidine with oxaliplatin (FOLFOX or CAPOX) for 3 to 6 months. These guidelines are based on data from phase III randomized controlled trials[7-11]. However, most of these clinical trials were limited by stringent inclusion and exclusion criteria, which precluded the broad participation of older adults[12].

Apart from age related decline in organ functions, older adults are more likely to have comorbid conditions, which can potentially complicate the administration of adjuvant chemotherapy[13,14]. However, age is not a robust surrogate marker for functional status and should not be used as a sole criterion to exclude patients from receiving treatment. A comprehensive geriatric assessment (CGA) can provide a better overall assessment of the functional status of older adults to guide the use of chemotherapy[15].

Meanwhile, real-world evidence refers to the analysis of data collected from routine clinical practice, outside the context of trials[16]. To date, real-world studies have also identified that older adults are less likely to receive adjuvant chemotherapy for colon cancer even though they stand to derive some benefit from treatment[17-20].

In this review, we will discuss the standard of care for stage II and III colon cancer, participation of older adults in clinical trials, specific challenges in the management of this population, and summarize data from clinical trials and data from real-world evidence on the use of adjuvant chemotherapy in older adults.

CLINICAL TRIALS OF ADJUVANT CHEMOTHERAPY IN COLON CANCER

Evolution of fluoropyrimidines
The benefit of adjuvant chemotherapy with 5-FU and levamisole was first apparent in a small randomized trial from the late 1980s[21,22]. The National Surgical Adjuvant Breast and Colon Project (NSABP) C-01 study and a subsequent meta-analysis further confirmed this disease free survival (DFS) benefit[23,24]. This was followed by another study that observed a 40% reduction in recurrence and a 33% improvement in overall survival (OS) among patients with stage III colon cancer who were treated with 12 months of 5-FU and levamisole[25], resulting in this being established as the standard adjuvant chemotherapy for colon cancer (Figure 1).

The next decade of treatment was marked by the eventual omission of levamisole due to its inefficacy, and the modulation of 5-FU and leucovorin into different regimens, including the “Mayo” (bolus low-dose LV and 5-FU daily × 5), “Roswell Park” (weekly high-dose LV and bolus 5-FU), and “de Gramont’s LV5FU2” (LV and bolus 5-FU plus infusion)[26-29]. Although none of the three regimens proved to be superior, LV5FU2 became the most preferred regimen because it was significantly
Figure 1  Timeline of evolution of adjuvant chemotherapy in colon cancer.

| Year | Event |
|------|-------|
| 1992 | INT-009 6-month FU regimen superior to 5-FU bolus |
| 1993 | NSABP C-04 5-FU-leucovorin superior to 5-FU-bolus |
| 1994 | NSABP C-07 5-FU-leucovorin plus oxaliplatin (FOLFOX) superior to 5-FU-leucovorin |
| 1995 | MOSAIC (Multicenter International Study of Oxaliplatin/5-FU/Leucovorin) study compared six months of adjuvant FOLFOX4 with LV5FU2 in patients with stage II and III colon cancer, and showed a 7.5% improvement in five-year DFS [hazard ratio (HR) = 0.78; \(P = 0.005\)], and 4.2% improvement in six-year OS (HR = 0.80; \(P = 0.023\)) with the addition of oxaliplatin in those with stage III disease\(^{30}\). Although there was a modest benefit in DFS, there was no OS benefit in stage II colon cancer at six and ten years, respectively\(^{31}\). Based on this trial, six months of adjuvant chemotherapy with FOLFOX became the new standard of care for patients with stage III colon cancer. The NSABP C-07 and NO16968 trials demonstrated similar DFS and OS benefits with the addition of oxaliplatin to bolus 5-FU/leucovorin or capecitabine (CAPOX), when compared to bolus 5-FU/leucovorin\(^{32,33}\). While the C-07 study included patients with stage II and III colon cancer, the latter study exclusively focused on those with stage III disease. Although irinotecan is active in advanced settings, its addition to 5-FU/leucovorin as adjuvant treatment in stage II and III colon cancer did not show any incremental benefit across three different randomized trials\(^{34-36}\). Furthermore, the addition of bevacizumab or cetuximab to FOLFOX was also not associated with any improvements in DFS or OS\(^{37-40}\). |
Table 1  Landmark trials for the combination of adjuvant chemotherapy with oxaliplatin and fluoropyrimidines in resected colorectal cancer

| Clinical Trial | Regimen | Patients (n/age) | Stage | DFS | OS |
|----------------|---------|-----------------|-------|-----|----|
| MOSAIC, 2004   | FOLFOX4 vs LV5FU2 | 2246 Age 18-75 77%, > 65 yr (34.6%) | II/III 40% Stage II | 5-yr 73.3% vs 67.4% 6-yr 72.9% vs 68.7% | For stage III No benefit for stage II at 6-yr and 10-yr |
| NSABP-C-07, 2007 | Weekly bolus 5-FU/LV ± Oxaliplatin (FLOX) | 2407 396, > 70 yr (16.4%) 695 Stage II (28.8%) | II/III | 4-yr 73.2% vs 67.0% | N/A Unplanned subset analyses suggested no benefit for patients > 70 yr (71.6% vs 76.3%) |
| NO16968, 2015  | CAPOX (XELOX) vs 5-FU/Leucovorin (C. Mayo/R. Park) | 1886 409, > 70 yr (21.6%) | III | 7-yr 63% vs 56% 7-yr 73% vs 67% | HR = 0.86 (95%CI: 0.64-1.16) HR = 0.91 (95%CI: 0.66 to 1.26) |

DFS: Disease free survival; HR: Hazard ratio; OS: Overall survival.

collaboration performed a pooled analysis of 12834 patients enrolled across six randomized trials in order to evaluate the non-inferiority of three months of adjuvant CAPOX or FOLFOX therapy as compared to six months of treatment in stage III colon cancer[11]. Although non-inferiority could not be confirmed in the overall population, three months of therapy was non-inferior to six months in lower risk patients (T1-3 and N1), particularly with CAPOX. Notably, in patients with T4 and/or N2 disease, six months of chemotherapy was superior to three months. Since these results were preliminary and OS data are not yet mature, both three and six months of adjuvant chemotherapy in low risk stage III colon cancer remain reasonable options. However, six months continues to be the standard duration when using single agent fluoropyrimidines.

Stage II colon cancer

Although the benefit of adjuvant chemotherapy has been proven in clinical trials of patients with stage III colon cancer, the more modest DFS and OS benefits seen in stage II disease has prompted the need to categorize patients into low and high risk groups based on clinico-pathological factors[23,41]. The four randomized clinical trials that included predominantly stage II colon cancer patients failed to show consistent benefits of adjuvant chemotherapy[42-45]. A detailed description of the role of adjuvant chemotherapy for stage II colon cancer is beyond the scope of this review. However, there is general agreement that adjuvant treatment with a fluoropyrimidine may benefit some patients with resected stage II colon cancer when specific high features are present. These high-risk features typically include, but are not limited to, colonic obstruction or localized perforation at presentation, poorly differentiated histology, T4 lesion, fewer than 12 nodes sampled, perineural, vascular or lymphatic invasion, and close/indeterminate or positive margins[4-6]. The role of microsatellite instability (MSI) in decision-making for adjuvant chemotherapy is still emerging; however, data suggest a high risk of treatment resistance to single agent fluoropyrimidines in MSI-high tumors[46-48]. While additional benefit of oxaliplatin has not been proven in patients with stage II colon cancer, this is likely to overcome fluoropyrimidine resistance in those with MSI-high status, based on a small exploratory analysis from the MOSAIC trial[7].

CLINICAL TRIAL PARTICIPATION OF OLDER ADULTS

Despite cancer being a disease of advanced age, older patients are under-represented in the majority of clinical trials[49-52]. A paradox exists whereby patients aged greater than 65 years constitute approximately 70% of the overall population with colorectal cancer, but this age group represents only 30% of clinical trial participants[49-52]. The main reasons that many older patients with colorectal cancer are excluded from studies include: previous or concomitant cancer treatments, comorbid conditions or
medications, and poor performance status[39]. Interestingly, one-third of “eligible” older patients are still not invited to participate in trials, driven by the observation that physicians are less likely to discuss and/or offer clinical trials to older patients with cancer[38,39].

There has been little change in this regard over last two decades, even though representation of other marginalized sub-groups such as women and ethnic minorities has improved[55-58]. An upper numerical age limit continues to be a common exclusion factor across contemporary clinical trials, despite recommendations by many major international societies that encourage the recruitment of older patients and the adoption of criteria based on physiological age rather than chronological age[59,60].

OLDER ADULTS: SPECIFIC ISSUES

Age-related decline in organ function
There are well described age-related deteriorations in organ function including in the hepatic, renal, cardiovascular, central nervous, and hematopoietic systems[61,62]. This leads to loss of physiologic reserve, which decreases the threshold for decompensation when faced with stressors, such as chemotherapy. Declining hepatic and renal function can potentially expose older patients to oxaliplatin and capecitabine at higher peak concentrations for a longer duration, respectively[62]. Moreover, due to potential muscle loss associated with aging, serum creatinine is a less reliable marker to assess renal function[54,63]. Similar deteriorations in bone marrow reserve that come with aging can potentiate chemotherapy dose reductions and delays, and also exacerbate the risk of febrile neutropenia in older adults[61].

Comorbid medical conditions
Patients older than 75 years have a median of five comorbid medical conditions. These may include anemia, cardiovascular disease, chronic obstructive airway disease, diabetes, previous cancer, and renal disease[13,14]. Charlson’s comorbidity index is one of the available tools to quantify these comorbidities, and a score of more than 2 has been independently associated with an increase in mortality among patients with colorectal cancer[65,66]. The interaction of comorbid conditions with the administration of adjuvant chemotherapy is rather complex. While the presence of severe comorbid conditions may outweigh the risk associated with adjuvant chemotherapy, patients with multiple well-control medical conditions are still likely to benefit from cancer treatment[67]. The presence of comorbid conditions can also increase the toxicity due to chemotherapy. Capecitabine, for example, can cause severe side effects in the presence of renal dysfunction, as it is excreted by the kidneys[68]. Moreover, capecitabine and 5-FU can lead to life-threatening coronary vasospasms that can result in further deterioration of cardiac function in those with pre-existing cardiovascular disease[69,70].

Pharmacokinetics of chemotherapeutic drugs
There are significant age-based alterations in pharmacokinetics of chemotherapeutic drugs. For example, the absorption of capecitabine may be affected due to worsening splanchnic blood flow, secretion of digestive enzymes, and gut motility among older patients[71]. The distribution of drugs is also affected by an increase in fat content and a decrease in intracellular water with advanced age, leading to a reduction in the peak concentration and contributing to longer half-lives of drugs[72]. Furthermore, declining hepatic and renal function can affect the metabolism and excretion of chemotherapeutic drugs[73,74].

Pharmacodynamics of chemotherapeutic agents
Cancer in older individuals develops from senescent cells, which are unable to undergo apoptosis, and hence, these cells are more likely to be resistant to chemotherapeutic agents that act by apoptosis[73]. Decreased angiogenesis in tumors of older adults may also lead to decreased delivery of drugs to the neoplastic cells[74]. Moreover, reduced levels of dehydropyrimidine dehydrogenase in older patients may cause delayed clearance of fluoropyrimidines, subsequently leading to increased adverse events with the use of capecitabine or 5-FU[75].

Polypharmacy
While 90% of the older population uses at least one medication, the average number of drugs is four per patient[76]. This predisposes older patients to potentially harmful drug interactions, which can negatively impact adherence to additional chemotherapy pills (capecitabine), as well as oral supportive medications that combat chemotherapy
related adverse effects\cite{77,78}.

**Quality of life**

Quality of life should always be considered in treatment decision making, but it is particularly prioritized in older patients since aggressive use of chemotherapy may compromise their daily activities and overall wellbeing. There are limited data that accurately describe the effect of chemotherapy on the quality of life of older patients with colorectal cancer\cite{79}. However, there is recognition that older adults are less willing to endure the side-effects of chemotherapy, as compared to younger patients\cite{80}. This should not be presumed for all older patients with cancer and individual preferences must be considered when discussing the benefits and risks of chemotherapy. Further, increased anxiety and depression have been reported in older individuals at diagnosis of cancer\cite{81}. However, older adults who know about the diagnosis and prognosis of cancer are able to better cope with the anxiety compared with those who do not know the details\cite{82}. Therefore, a well-informed decision-making process with older adults is likely to improve the psychosocial aspects and better maintain quality of life.

### ASSESSMENT OF FUNCTIONAL STATUS IN OLDER ADULTS

**Performance status**

Chronological age is a poor surrogate of physiologic and functional status of older patients\cite{83}. Performance status (PS) as assessed by physicians is commonly employed in oncology to ascertain the functional status of patients; the most validated scales include the Eastern Cooperative Oncology Group PS (ECOG PS), and Karnofsky PS (KPS)\cite{84,85}. In general, patients with ECOG PS > 2 and KPS < 60 are considered to be poor candidates for chemotherapy. However, data suggest that clinician assessments of functional status tend to underestimate the true functional status of older patients\cite{86}.

**CGA**

A CGA involves a multidimensional evaluation of older patients, including their functional status, comorbid medical conditions, cognition, nutritional status, psychological state, socio-economic condition, and a record of the patient’s medications\cite{87}. The purpose of a CGA is to identify frail older patients who may be able to tolerate chemotherapy, as well as fit older patients who may have a higher likelihood of developing chemotherapy related side effects. Several studies have demonstrated how CGA can add information to the conventional ECOG PS in older patients\cite{15,88,89}, help in cancer treatment decision making\cite{15,90}, predict complications and adverse events from chemotherapy\cite{91-94}, and improve pain control, mental health, and well-being\cite{95}. Although there is no uniform CGA tool, various models have been implemented in different settings that encompass the core domains of the assessment\cite{96}. A combination of a self-administered questionnaire and a healthcare provider assessment is most often utilized. There is considerable debate as to which older patients actually benefit from the resource intensive CGA. In response to this, pre-CGA screening tools have also been developed\cite{97-99}. However, a systematic review concluded that there is limited sensitivity and specificity of these tools\cite{100}. The consensus guidelines by the American Society of Clinical Oncology (ASCO) and the International Society of Geriatric Oncology (SIOG) recommend the routine use of CGA in patients aged more than 65 years with cancer, but to date there has been variable adoption of CGA in busy routine clinical practices\cite{101,102}.

### CLINICAL TRIAL AND REAL-WORLD DATA OF OLDER ADULTS WITH STAGE II AND III COLON CANCER

**Fluoropyrimidines**

Due to poor representation in clinical trials, evidence for the efficacy of fluoropyrimidines as adjuvant chemotherapy in stage III colon cancer among older adults is derived mainly from pooled analysis of individual patient-level data from randomized trials, and data from population-based real-world studies. In particular, there was a large pooled analysis that included information from 3351 patients with stage II or III colon cancer from seven randomized phase III clinical trials evaluating the role of 5-FU (five with leucovorin, and two with levamisole), which categorized
patients into four groups according to age (< or = 50, 51 to 60, 61 to 70, and > 70 years) [99]. Adjuvant treatment was associated with improved OS (HR = 0.76; 95% CI: 0.68-0.85, P < 0.001), superior time to recurrence (HR = 0.68; 95% CI: 0.60-0.76; P < 0.001), and better 5-year OS (64% vs 71%). There were 506 patients aged more than 70 years, and no significant interaction was observed between age and treatment efficacy. Moreover, the incidence of adverse events was similar in the four age groups, except there was a higher incidence of leukopenia in patients older than 70 years. Although this analysis suggests similar benefits of chemotherapy in older patients as compared to their younger counterparts, findings were limited by the representation of only fit older patients who met the stringent inclusion criteria of clinical trials [92,93,94,95,96].

Population-based studies complement clinical trials by providing information regarding the efficacy of adjuvant chemotherapy with 5FU in unselected patients in the real-world setting (Table 2). One such study analyzed data of patients aged more than 65 years diagnosed with stage III colon cancer from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program and Medicare [107]. Of the 4738 patients included in that analysis, 52% received adjuvant chemotherapy, and there was a 32% (HR = 0.66; 95% CI: 0.60-0.73) relative reduction in mortality with 5-FU based treatment. In a subsequent published study that used the same database, 51% (3672 out of 7182) patients aged more than 65 years received SFU based adjuvant chemotherapy within 6 months of surgery [108]. In that study, patients were categorized into five age groups (66-69, 70-74, 75-79, 80-84, and > 85 years) to analyze the effect of increasing age. While patients in all age groups derived benefit from adjuvant chemotherapy, the magnitude was not uniform across all ages whereby patients aged 70-74 years experienced 14% greater survival when compared to 8% in patients aged 80 to 84 years.

Another study that analyzed the use and efficacy of adjuvant chemotherapy in 85,934 patients across all ages with stage III colon cancer residing in community settings concluded that the benefit of adjuvant chemotherapy was similar in patients aged more than 80 years [109].

Data from similar studies that examined the proportion of patients who completed the planned duration of chemotherapy suggest that one-third of older patients discontinued adjuvant treatment prematurely [108,109]. Apart from advanced age, other factors associated with early termination of chemotherapy include physical frailty, treatment complications, and lack of social and psychological support.

In the previously described X-ACT trial that randomized stage III colon cancer patients to either capecitabine or 5-FU/leucovorin, 396 of 1987 enrolled patients were older than 70 years. Although older patients required more frequent dose modifications of capecitabine when compared to younger patients (65% vs 55%), capecitabine was non-inferior to 5-FU/leucovorin in the subgroup analysis involving patients aged more than 70 years [5-year OS, 68.8% and 65.0% (HR = 0.91, 95% CI: 0.65-1.26)] [10]. However, capecitabine should still be used with caution in very old patients because of the increased toxicity associated with declining renal function [110]. The efficacy and safety data for UFT in older adults are very limited. A small trial of 63 patients aged greater than 70 years shows a favorable toxicity profile [111].

**Combination chemotherapy with oxaliplatin**

Unlike fluoropyrimidines, the benefit of adding oxaliplatin in the adjuvant treatment of older patients with resected colon cancer is more controversial. The main driver for this is the under-representation of the older population in the landmark MOSAIC and NSABP C-07 trials [112,113]. The MOSAIC trial excluded those older than 75 years, and only 14% (315 of 2246) of patients were aged 70 to 75 years so the subgroup analysis was underpowered to show any benefit of FOLFOX as compared to 5FU/leucovorin. The HRs for DFS and OS were 0.93 (95% CI: 0.64 to 1.35) and 1.10 (95% CI: 0.73 to 1.65), respectively [112]. While the NSABP C-07 study did not apply an upper age limit to enrollment, only 14% of the participants were aged more than 70 years. Similar to MOSAIC’s subgroup analysis, there was no observed DFS and OS advantage with the addition of oxaliplatin among patients older than 70 years [113]. Moreover, the Adjuvant Colon Cancer End Points (ACCENT) group analyzed the pooled data of 14528 patients from seven randomized trials. Of these, 2575 patients were older than 70 years. Although there was a 3-year DFS benefit with combination chemotherapy, no incremental OS benefit was seen in older patients [112]. Likewise, a systematic review published by Cancer Care Ontario concluded little additional benefit of oxaliplatin in patients older than 70 years of age [114].

In contrast, the NO16968 trial randomized 1886 patients with stage III colon cancer to CAPOX or 5-FU/leucovorin. There was a preplanned subgroup analysis which demonstrated a similar magnitude of benefit in younger and older patients [115]. Furthermore, a pooled analysis of four clinical trials evaluated the role of oxaliplatin
| Ref.          | Study design                  | n/stage                        | Age selection                          | Treatment arms/parameters                                                                 | Conclusion                                                                 |
|--------------|-------------------------------|-------------------------------|----------------------------------------|--------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Sargent et al [103], 2001 | Pooled analysis 7 trials | 3351, stage II/III | ≤ 50, 51-60, 61-70, and > 70 yr | Fluorouracil plus leucovorin or levamisole vs surgery alone | Same benefit from fluorouracil-based adjuvant therapy as their younger counterparts |
| Sundararajan et al [17], 2002 | Retrospective cohort | 4768, node-positive | 65 years of age or older | Association of 5-FU adjuvant therapy with survival | 5-FU therapy is significantly associated with reduced mortality in older patients |
| Zuckerman et al [104], 2009 | Observational, retrospective cohort | 3016, stage III | aged 66 and older | 5-FU or leucovorin within 6 mo after surgery | Elderly patients had a significant survival benefit associated with adjuvant chemotherapy |
| Jessup et al [105], 2005 | Prospective data | 85934, stage III | < 60, 60-69, 70-79, > 80 yr | Adjuvant chemotherapy usage and 5-yr survival | Elderly patients have the same benefit as younger patients but are less frequently treated |
| Neugut et al [115], 2006 | Retrospective database | 1722, stage III | ≥ 65 years of age | Early discontinuation of FU-based chemotherapy | High percentage of early treatment discontinuation in the elderly population |
| Dobie et al [105], 2006 | Retrospective SEER analysis | 3193, stage III | 65 years and older | Adjuvant chemotherapy completion and its relation to 3-year cancer mortality | Incomplete adjuvant chemotherapy associated to physical frailty and treatment complications |
| McCleary et al [115], 2013 | Pooled analysis, ACCENT group | 14528, stage II/III | age < 70 and age ≥ 70 years | Impact of age on colon cancer recurrence and mortality after adjuvant therapy | Reduced benefit from adding oxaliplatin to fluoropyrimidines in the adjuvant setting for patients > 70 years |
| Meyers et al [114], 2017 | Systematic review | Stage II and III | age < 70 and age ≥ 70 years | Benefit from adjuvant chemotherapy (5-fluorouracil /leucovorin/ oxaliplatin or capecitabine/ oxaliplatin) | Patients with high-risk stage II disease may benefit from adjuvant chemotherapy |
| Green et al [115], 2019 | Retrospective SEER-Medicare database analysis | 31990, stage II/III | Aged 66-69, 70-74, 75-79, 80-84, 85-89 and 90+ | Use and outcomes of adjuvant chemotherapy | Administration of adjuvant chemotherapy for colon cancer decreases with advancing age, but improved outcomes are seen in stage III patients under 90 years of age |
| Sanoff et al [117], 2012 | Retrospective data source analysis | 4060, stage III | < 50, 50-64, 65-69, 70-74 yr | Oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy | The addition of oxaliplatin to 5-FU appears to be associated with better survival among patients receiving adjuvant colon cancer treatment in the community |

5-FU: 5-fluorouracil; SEER: Surveillance, Epidemiology, and End Results; ACCENT: Adjuvant Colon Cancer End Points.

in patients aged more than 70 years. This particular analysis excluded the MOSAIC study because of inaccessibility to patient level data and the NSABP C-07 study due to its use of an outdated regimen. A total of 4819 patients from four randomized trials were examined of whom 904 patients were more than 70 years old. It concluded that the addition of oxaliplatin improved DFS and OS in both younger and older patients, although there was a modest attenuation in the survival benefit (DFS, < 70 years: HR = 0.68; 95%CI: 0.61-0.76; P < 0.0001; > 70 years: HR = 0.77; 95%CI: 0.62-0.95; P = 0.014).

With the increasing number of patients that are considered “older”, the significance of real-world evidence and its capacity to complement randomized trials are
increasingly being recognized\textsuperscript{[16]}. However, similar to the case with clinical trial data, results from real-world evidence studies that analyzed the outcomes of oxaliplatin in older patients are conflicting. The largest contemporary real world study of patients older than 65 years included 31990 patients with stage II/III colon cancer from the SEER/Medicare database and grouped patients by age at five year intervals\textsuperscript{[17]}. Overall, there was a gradual decline in the use of adjuvant chemotherapy, ranging from 57\% in 66-69 years old to 1\% in those aged more than 90 years. While the benefit of adjuvant chemotherapy was seen in all patients less than 90 years, those with stage II disease had increased mortality with adjuvant chemotherapy. Of note, the SEER/Medicare does not include data on high risk features of stage II colon cancer, so this finding should be interpreted with caution. Likewise, the authors did not perform an analysis based on type of chemotherapy because there was poor sensitivity in identifying specific chemotherapeutic agents\textsuperscript{[19]}. In other studies that linked with SEER/Medicare database, oxaliplatin in stage III colon cancer demonstrated OS benefit in the age group of 70-74 years old (HR = 0.66; 95\%CI: 0.52-0.94)\textsuperscript{[18]}. However, there was no significant incremental benefit of oxaliplatin in patients older than 75 years (HR = 0.84; 95\%CI: 0.69-1.04)\textsuperscript{[19]}.

While there is no clear consensus regarding the impact of combination chemotherapy in older adults, data on its safety are reassuring in that there were no increases in emergency department use, hospitalizations, and early deaths\textsuperscript{[20]}. In patients older than 75 years, the odds of developing chemotherapy induced nausea and vomiting (odds ratio (OR) = 2.14; 95\%CI: 1.73-2.65), as well as neutropenia (OR = 17.3; 95\%CI: 9.80-30.42) were higher in patients receiving FOLFOX as compared to 5FU alone. However, no differences were observed in rates of diarrhea, dehydration, infection, or acute coronary events.

**Stage II colon cancer in older patients**

The benefit of adjuvant chemotherapy in resected stage II colon cancer is debatable, with most guidelines recommending that it be considered only in patients with high risk features. Moreover, data of older patients with stage II colon cancer are scarce, with the majority of current treatment recommendations extrapolated from those in younger patients. A SEER/Medicare database study identified 24847 patients aged more than 65 years with stage II colon cancer, of whom 75\% had at least one high risk feature, and 20\% of these received adjuvant chemotherapy. There was no difference in 3-year OS in treated and untreated patients (HR = 1.03; 95\%CI: 0.94-1.13; \(P = 0.47\))\textsuperscript{[21]}. This raises the question of benefit of adjuvant chemotherapy in older adults with stage II colon cancer. The SIOG recommendations on treatment of older adults with stage II colon cancer acknowledge the limited data in this clinical situation\textsuperscript{[22]}. However, older age by itself should not be a sole exclusion criterion to offer adjuvant chemotherapy in stage II colon cancer with high-risk features. Thus, a discussion with older patients with high-risk stage II colon cancer regarding a small potential benefit and possible toxicities must be conducted while considering the patients’ preferences.

**CONCLUSION**

Underrepresentation of older patients in clinical trials of adjuvant chemotherapy for stage II and III colon cancer has contributed to significant gaps in our understanding of the true benefit of such therapy. However, real-world evidence and pooled analysis from these clinical trials have allowed oncologists to arrive at some agreement. In older patients with stage II colon cancer, there are limited data to suggest efficacy of adjuvant chemotherapy, even among those with high-risk features. In contrast, single agent fluoropyrimidine appears to provide similar benefit in older patients as younger patients. There are contradicting data on the incremental value of adding oxaliplatin to fluoropyrimidines in stage III colon cancer. This is largely because most of the analyses were either post hoc (exploratory) in design or underpowered to reach definitive conclusions. Likewise, available data from real-world evidence are limited by inherent selection bias and confounding by indication. However, further real-world evidence using novel statistical methods eliminating such confounding and biases is likely to shine further light on controversies which are unlikely to be resolved by future clinical trials. As we move forward, the integration of CGAs of older adults may represent a more useful and reliable method to select appropriate older patients for adjuvant chemotherapy. This is due to the observation that chronological age is a poor proxy for functional status and should not be used as a standalone factor for treatment decision-making since it may unintentionally deny older patients the potential benefits of adjuvant chemotherapy.
REFERENCES

1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

2 SEER. Cancer of the Colon and Rectum - Cancer Stat Facts [Internet]. [accessed 14 February 2020]. Available from: URL: https://seer.cancer.gov/statfacts/html/colon.html

3 Cappell MS. Pathophysiology, clinical presentation, and management of colon cancer. Gastroenterol Clin North Am 2008; 37: 1-24, v [PMID: 18315357 DOI: 10.1016/j.gtc.2007.12.002]

4 Labianca R, Noddinger B, Beretta GD, Mosconi S, Mandalia M, Cervantes A, Arnold D; ESMO Guidelines Working Group. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6: vi64-vi72 [PMID: 24078664 DOI: 10.1093/annonc/mdt354]

5 Costas-Charavari A, Nandakumar D, Temic S, Lopes G, Cervantes A, Cruz Correa M, Engineer R, Hamashima C, Ho GF, Hutzil FD, Malekzadeh Moghani M, Sharrara AI, Stern MC, Teh C, Vázquez Manjarrez SE, Verjee A, Yantis R, Shah MA. Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline. J Glob Oncol 2019; 5: 1-19 [PMID: 30800158 DOI: 10.1200/JGO.18.00214]

6 National Comprehensive Cancer Network. Colon Cancer (Version 1.2020). [accessed 14 February 2020]. Available from: URL: http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf

7 André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scraya A, Hijkstra T, Tabernero J, Van Laethem JL, Banzu M, Maartense E, Emwueli E, Carlsson GU, Scheithauer W, Papamichael D, Möhler M, Landolfo S, Demetter P, Colote S, Tourkind C, Louvier D, Auval F, Filéou JF, de Gramont A. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAC Study. J Clin Oncol 2015; 33: 4176-4187 [PMID: 26527776 DOI: 10.1200/JCO.2015.63.4238]

8 Kuechler JP, Wierand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JW, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman UK, Laney IV, Kaneshiro N, Wolmark N. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage III and II colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198-2204 [PMID: 17448581 DOI: 10.1200/JCO.2006.08.2974]

9 Twelves C, Wong A, Nowacki MP, Abt M, Burris H, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulis V, Husseini F, Jodrell D, Koralesski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schiller J, Seitz F, Stacab T, Tjabouka W, Van Hazel G, Zolomski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2606-2607 [PMID: 15987918 DOI: 10.1056/NEJMoa0414116]

10 Haller DG, Tabernero J, Maroun J, De Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Ritterweg K, Schmoll HJ. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29: 1465-1471 [PMID: 21385394 DOI: 10.1200/JCO.2010.33.6297]

11 Grothey A, Sobero AF, Shields AF, Yoshino T, Paul J, Taielb J, Soulaglas J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Ichikawa K, Meyer IA, Meyers JF, Riefer LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Ivens T. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. J Natl Cancer Inst 2018; 110: 1177-1188 [PMID: 29390444 DOI: 10.1093/annonc/mdy1730765 DOI: 10.1002/1097-0142(20191001)0:17+<1995::AID-CNCR2820741702>3.0.CO;2-Y]

12 McCleary NJ, Meyerhardt JA, Green E, Yothers G, de Gramont A, Van Cutsem E, O’Connell M, Twelves CJ, Saltz LB, Haller DG, Sargent DJ. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 2013; 31: 2600-2606 [PMID: 23733765 DOI: 10.1200/JCO.2013.49.6638]

13 Yancik R, Wesley MN, Ries LA, Hvalvik RJ, Long S, Edwards BK, Yates JW. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 1998; 82: 2123-2134 [PMID: 9610691]

14 Yancik R, Ries LA. Cancer in older persons. Magnitude of the problem--how do we apply what we know? Cancer 1994; 74: 1995-2003 [PMID: 8087762 DOI: 10.1002/1097-0142(19940101)74:7<1995::AID-CNCN2820740172>3.0.CO;2-v]

15 Kenis C, Bron D, Libert Y, Decoster L, Van Puyvelde K, Scallet P, Cornette P, Pepsucks T, Luce S, Langenaeken R, Raeschaert M, Allepaerts S, Van Rijswijk R, Milsen K, Flamang N, Lobelle JP, Wildiers H. Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. Ann Oncol 2013; 24: 1306-1312 [PMID: 23293115 DOI: 10.1093/annonc/mds619]

16 Khozin S, Blumenfeld GM, Pazdur R. Real-world Data for Clinical Evidence Generation in Oncology. J Natl Cancer Inst 2017; 109 [PMID: 29054937 DOI: 10.1093/jnci/djx187]

17 Sundararajan V, Mirta N, Jacobson JS, Gramm VR, Heitjan DF, Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002; 136: 349-357 [PMID: 11874307 DOI: 10.7326/0003-4819-136-5-20020530-00007]

18 Schrag D, Cramer LD, Bach PB, Clegg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001; 93: 850-857 [PMID: 11396354 DOI: 10.1093/jnci/93.11.850]

19 Kahn KL, Adams JL, Weckes JC, Chrischilles EA, Schrag D, Ayanian JZ, Kiefle CJ, Ganz PA, Bhoopatham N, Potosky AL, Harrington DP, Fletcher RH. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA 2010; 303: 1037-1045 [PMID: 20233821 DOI: 10.1001/jama.2010.272]

20 Iwashyna TJ, Lumont JB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 2002; 20: 3992-3998 [PMID: 12351596 DOI: 10.1200/JCO.2002.03.083]

21 Fluorouracil as an adjuvant to colorectal cancer surgery: the breakthrough that never was. JAMA 1976; 236: 1935-1936 [PMID: 895949]

22 Laurie JA, Moertel CG, Fleming TR, Wierand HS, Leib JE, Rubin J, McCormack GW, Gerstner JB, Krook JE, Malliard J. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic J Clin Oncol 1989; 7: 1447-1456 [PMID: 2778478 DOI: 10.1200/JCO.1989.7.10.1447]
Adjuvant chemotherapy in older adults with colon cancer

Batra A

Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. *N Engl J Med* 1980; 322: 352-358 [DOI: 10.1056/NEJM198003203220602]

Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH. Levamisole and fluorouracil and fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. *J Clin Oncol* 1999; 17: 3553-3559 [DOI: 10.1200/JCO.1999.17.8.3553]

Haller DG, Catalan JS, O'Rourke MA, Frontiero MS, Jackson DVD, Mayer RJ. Phase III study of fluorouracil, levamisole, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. *J Clin Oncol* 2005; 23: 8671-8678 [DOI: 10.1200/JCO.2004.00.5666]

André T, Colin P, Louvet C, Gamelin E, Bouché A, Achille E, Colbert N, Bouzzi C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Buyse M, de Gramont A. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. *J Clin Oncol* 2003; 21: 2896-2903 [DOI: 10.1200/JCO.2003.03.065]

André T, Quirinaux E, Louvet C, Colin P, Gamelin E, Bouché A, Achille E, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Lledo G, Raoul Y, Debrus I, Buyse M, de Gramont A. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. *J Clin Oncol* 2007; 25: 3732-3738 [DOI: 10.1200/JCO.2007.12.2234]

Lemmersky BC, Wiegand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Youths G, Buyse M, Wolmark N. Oral uracil and tegafur/leucovorin compared with fluorouracil and levamisole in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. *J Clin Oncol* 2006; 24: 2059-2064 [DOI: 10.1200/JCO.2005.04.7498]

André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topcham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIK) Investigators. Oxaliplatin, fluorouracil, and levamisole as adjuvant treatment for colon cancer. *N Engl J Med* 2004; 350: 2243-2251 [DOI: 10.1056/NEJMoa032709]

André T, Boni C, Navarro M, Tabernero J, Hickish T, Topcham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIK trial. *J Clin Oncol* 2009; 27: 3109-3116 [DOI: 10.1200/JCO.2008.20.6771]

Tournigand C, André T, Achille E, Lledo G, Mery-Mignard D, Iglesias D, Couteau C, Buyse M, de Gramont A; PETACC-8 Study Investigators. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. *Lancet Oncol* 2011; 12: 293-301 [DOI: 10.1016/S1470-2045(10)70227-X]

Salez JB, Niedzwiezki DJ, Hollis D, Goldberg RM, Haintel A, Thomas JP, Field LS, Mayer RJ. Irinotecan fluorouracil plus levamisole is superior to fluorouracil plus levamisole alone as adjuvant treatment for stage III colon cancer: results of CALGB 89883. *J Clin Oncol* 2007; 25: 3456-3461 [DOI: 10.1200/JCO.2007.11.2144]

Ychou M, Holenberner W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, Shacham-Shmueli E, Rivera F, Kwock-Keung Choi C, Santoro A. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. *Ann Oncol* 2009; 20: 1964-1970 [DOI: 10.1093/annonc/mdp236]

Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, Topham C, Tabernero J, André T, Sobrero AF, Mini E, Greil R, Di Costanzo F, Collette L, Cisar L, Zhang X, Khayat D, Clingan P, Bridgewater J, Table 1: Overall survival of the PETACC-3 trial. *J Clin Oncol* 2009; 27: 3117-3125 [DOI: 10.1200/JCO.2008.20.6663]

Allegre CJ, Youthers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, Atkins JN, Seay TE, Fehrenbacher L, Goldberg RM, O'Reilly S, Chu L, Azar CA, Lopa S, Wolmark N. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. *J Clin Oncol* 2011; 29: 749-756 [DOI: 10.1200/JCO.2010.30.0855]

de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im SA, Bodoky G, Salazar R, Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E, Makrutzki M, Shang A, André T, Hoff PM. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (PETACC-8): a phase 3 randomised controlled trial. *Lancet Oncol* 2012; 13: 1225-1233 [DOI: 10.1016/S1470-2045(12)70227-X]

Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Tuboedone SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quinney-Ernest JB, Webb TA, Farr GH Jr, Pockaj BA, Grothey A, Goldberg RM. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. *JAMA* 2012; 307: 1383-1393 [DOI: 10.1001/jama.2012.6013]

Taiès J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C; PETACC-8 Study Investigators. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. *Lancet Oncol* 2014; 15: 862-873 [DOI: 10.1016/S1470-2045(14)70227-X]

Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. *Lancet* 1995; 345: 939-944 [DOI: 10.1016/S0140-6736(95)91209-X]

Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tango CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. *J Clin Oncol* 1995; 13: 2936-2943 [DOI: 10.1200/JCO.2005.04.5666]
Adjuvant chemotherapy in older adults with colon cancer

Matsuda C, Ishiguro M, Teramukai S, Kajiwara Y, Fuji S, Kinugasa Y, Nakamoto Y, Kotsuka M, Sakamoto Y, Kurachi K, Maeda A, Komori K, Tomita N, Shimada Y, Takahashi K, Kotsuka K, Watanabe M, Mochizuki H, Nakagawa Y, Sugihara R. Adjuvant chemotherapy versus observation in patients with colon cancer: a randomised controlled trial. Lancet 2019; 393: 1568-76 [PMID: 30623805 DOI: 10.1016/S0140-6736(18)32632-1]

Schipper W, Samonig H, Schaben-Moser R, Greil R, Thököly B, Tschmelitsch J, Jagoditsch M, Steger GG, Jakobs R, Herbst F, Hofbauer F, Rahl H, Wohlmuth P, Grant M, Thaler J. Austrian Breast and Colorectal Cancer Study Group. A randomised-controlled trial of 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer 2017; 97: 1021-1027 [PMID: 27985886 DOI: 10.1038/jbc.2016.6040101]

Quasar Collaborative Group, Gray R, Barnwell J, Conaty A, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colon cancer: a randomised controlled trial. Lancet 2007; 370: 2020-2029 [PMID: 18083804 DOI: 10.1016/S0140-6736(07)61866-2]

Allegre CJ, Kim G, Kirsch IR. Microsatellite instability in colon cancer. N Engl J Med 2003; 349: 1774-1776; author reply 1774-1776 [PMID: 12968950 DOI: 10.1056/NEJM20031030103491815]

Kim GP, Colangelo LH, Wierds HS, Paik S, Kirsch IR, Wolmark N, Allegre CJ; National Cancer Institute. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007; 25: 767-772 [PMID: 17228023 DOI: 10.1200/JCO.2006.05.8172]

Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yethers G, Allegre C, Moore MJ, Gallinger S, Sargent DJ. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011; 103: 863-875 [PMID: 21597022 DOI: 10.1093/jnci/djr151]

Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol 2012; 30: 2036-2038 [PMID: 22547397 DOI: 10.1200/JCO.2012.41.64727]

Talarico L, Chen G, Puzdar R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004; 22: 4626-4631 [PMID: 15542812 DOI: 10.1200/JCO.2004.02.175]

Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montiello MJ, Housman SG, Escaich J. Participation of patients 65 years of age or older in cancer trials during 2003-2005. J Clin Oncol 2007; 25: 1383-1389 [PMID: 17663771 DOI: 10.1200/JCO.2006.08.0106]

Hutcheson LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer treatment trials. N Engl J Med 1999; 341: 2061-2067 [PMID: 10615079 DOI: 10.1056/NEJM199912303492176]

Canoui-Poitrine F, Lièvre A, Dayde F, Lopez-Tabrada-Ataz D, Baumgaertner I, Dubreuil O, Brunetti F, Coriat R, Malek K, Pernet S, Tourigny C, Hagege A, Apriacio T, Paillet F, Bastuji-Garin S. Inclusion of Older Patients with Cancer in Clinical Trials: The SAGE Prospective Multicenter Cohort Survey. Oncologist 2019; 24: e1351-e1359 [PMID: 31324663 DOI: 10.1634/theoncologist.2019-0166]

David SH, Unger JM, Gralow JR, Moinpour CM, Wozniak AJ, Goodwin JW, Lara PN Jr, Williams PA, Hutchins LF, Gotay CC, Albain KS. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). Oncologist 2012; 17: 1180-1190 [PMID: 22732596 DOI: 10.1634/theoncologist.2011-03848]

Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004; 291: 2720-2726 [PMID: 15187053 DOI: 10.1001/jama.291.22.2720]

Unger JM, Coltman CA, Crowley JJ, Hutchins LF, Martino S, Livingston RB, Macdonald JS, Blanke CD, Gandara DR, Crawford ED, Albain KS. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol 2006; 24: 141-144 [PMID: 16350670 DOI: 10.1200/JCO.2005.02.8928]

Freedman RA, Foster JC, Seisler DK, Laﬁky JM, Muss HB, Cohen JH, Mandelblatt J, Winer EP, Hudis CA, Partridge AH, Carey LA, Cirrincione C, Moreno-Aspina G, Kimmick G, Jatoi A, Hurria A. Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Protocol A151527. J Clin Oncol 2017; 35: 421-431 [PMID: 27992227 DOI: 10.1200/JCO.2016.69.4182]

Gouverneur A, Salvo F, Berdai D, Moore N, Fourrier-Réglat A, Noize P. Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review. J Geriatr Oncol 2018; 9: 15-23 [PMID: 28844343 DOI: 10.1016/j.jgo.2017.08.001]

Papamichael D, Audioso R, Horiot JC, Glimelius B, Sastre J, Mitry E, Van Cutsens E, Gosney M, Köhne CH, Aapro M. SIODG. Treatment of the elderly colorectal cancer patient: SIODG expert recommendations. Ann Oncol 2009; 20: 5-16 [PMID: 18922882 DOI: 10.1093/annonc/mdm532]

Zelman DM, Sussman JB, Chen X, Cigolle CT, Blais RM, Hayward RA. Evaluating the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med 2011; 26: 783-790 [PMID: 21286840 DOI: 10.1007/s10066-010-1629-x]

Sehl M, Sawhney R, Naem A. Physiological aspects of aging: impact on cancer management and decision making, part II. Cancer J 2005; 11: 461-473 [PMID: 16593480 DOI: 10.1007/10130404-20051100-00003]

Sawhney R, Sehl M, Naem A. Physiological aspects of aging: impact on cancer management and decision making, part I. Cancer J 2005; 11: 449-460 [PMID: 16393479 DOI: 10.1007/10130404-20051100-00004]

Launay-Vacher V, Chatelet E, Lichtman SM, Wildiers H, Steer C, Aapro M; International Society of Geriatric Oncology. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 2007; 18: 1314-1321 [PMID: 17631561 DOI: 10.1093/annonc/mdm111]

Swedj PK, Clark HD, Ramansothy K, Akbari A. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med 2003; 163: 356-360 [PMID: 12578517 DOI: 10.1001/archivni.163.3.356]

Hines RB, Chatla C, Bumpers HL, Waterlor JW, McGwin G Jr, Finkhouse E, Coffey CS, Posey J, Manne U. Predictive capacity of high comorbidity indices in estimating mortality after surgery for colon cancer. J Clin Oncol 2009; 27: 4339-4345 [PMID: 19652054 DOI: 10.1200/JCO.2009.22.4756]

Eriksen R, Horvath-Paló E, Iversen LH, Lash TL, Sørensen HT. Does comorbidity interact with colorectal cancer to increase mortality? A nationwide population-based cohort study. Br J Cancer 2013;
Batra A, et al. Adjuvant chemotherapy in older adults with colon cancer

109: 2005-2013 [PMID: 24022185 DOI: 10.1038/bjc.2013.541]

Gross CP, McAvay GJ, Guo Z, Tinetti ME. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer 2007; 109: 2410-2419 [PMID: 17510973 DOI: 10.1002/cncr.22272]

Walko CM, Lindley C. Capcitabine: a review. Clin Ther 2005; 27: 23-44 [PMID: 15763604 DOI: 10.1016/j.clinthera.2005.01.005]

Van Cutsem E, Hoff PM, Blum JL, Abt M, Osterwalder B. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 2002; 13: 484-485 [PMID: 11996484 DOI: 10.1093/annonc/mdf108]

Kosmas C, Kalistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, Karavelis A, Tasviris N. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008; 134: 75-82 [PMID: 17636239 DOI: 10.1007/s00432-007-0250-9]

Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med 1997; 13: 169-183 [PMID: 8955166]

Egorin MJ. Cancer pharmacology in the elderly. Semin Oncol 1993; 20: 43-49 [PMID: 8475409]

Campisi J. Aging and cancer: the double-edged sword of replicative senescence. J Am Geriatr Soc 1997; 45: 482-488 [PMID: 9100719 DOI: 10.1111/j.1532-5415.1997.00517.x]

Rockwell S, Hughes CS, Kennedy KA. Effect of host age on microenvironmental heterogeneity and efficacy of combined modality therapy in solid tumors. Int J Radiat Oncol Biol Phys 1991; 20: 259-263 [PMID: 1899412 DOI: 10.1016/0360-3016(91)90101-9]

Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995; 75: 11-17 [PMID: 7899663 DOI: 10.1002/1097-0142(19950101)75:1<11::aid-cncr16>3.0.co;2-n]

Vestal RE. Aging and pharmacology. Cancer 1997; 80: 1302-1310 [PMID: 9317183 DOI: 10.1002/1097-0142(19971001)80:10<1302::aid-cncr16>3.0.co;2-b]

Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002; 94: 652-661 [PMID: 11983753 DOI: 10.1093/jnci/94.9.652]

Tam-McDevitt J. Polypharmacy, aging, and cancer. Oncology (Williston Park) 2008; 22: 1052-1055, discussion 1055, 1058, 1060 [PMID: 18777955]

Sanoff HK, Goldberg RM, Pignone MP. A systematic review of the use of quality of life measures in colorectal cancer research with attention to outcomes in elderly patients. Clin Colorectal Cancer 2007; 6: 709-799 [PMID: 18039423 DOI: 10.3816/CCC.2007.n.039]

Yellen SB, Cella DF, Leslie WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst 1994; 86: 1766-1770 [PMID: 7966414 DOI: 10.1093/jnci/86.23.1766]

Given B, Given CW. Older adults and cancer treatment. Cancer 2008; 113: 3505-3511 [PMID: 19058145 DOI: 10.1002/cncr.23939]

Estapé T. Cancer in the Elderly: Challenges and Barriers. Asia Pac J Oncol Nurs 2018; 5: 40-42 [PMID: 29378132 DOI: 10.4103/apjon.apjon_52_17]

Hurria A. Geriatric assessment in oncology practice. J Am Geriatr Soc 2009; 57 Suppl 2: S24-S249 [PMID: 20122022 DOI: 10.1111/j.1532-5419.2009.02505.x][Available]

Oken MM, Creech RH, Torney DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655 [PMID: 7165009]

Karnofsky D, Burchenal J. The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of chemotherapeutic agents. New York, NY: Columbia University Press; 1949: 191-205

Rodin MB. Mobile SG. A practical approach to geriatric assessment in oncology. J Clin Oncol 2007; 25: 1936-1944 [PMID: 1748994 DOI: 10.1200/JCO.2006.20.2954]

Stuck AE, Siu AL, Wieland GD, Adams J, Rubenstein LZ. Comprehensive geriatric assessment: a systematic review of the utility of comprehensive geriatric assessment. J Clin Oncol 2007; 25: 3457-3465 [PMID: 17488994 DOI: 10.1200/JCO.2006.10.2954]

Kannel WB, Feinleib M, Belanger AJ, McNamara PM, Schillinger JM, Abbott RD. High blood pressure as an independent risk factor for stroke in the elderly. The Framingham Study. Stroke 1983; 14: 565-570 [PMID: 6124078 DOI: 10.1161/01.str.14.4.565]

Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, Vercelli M, Parodi S, Dal Lago D, Gioia F, Katheria V, Klapper S, Hansen K, Ramani R, Lachs M, Wong FL, Tew WP, Lichtman SM, Gajra A, Bhatia S, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM. Effect of comprehensive geriatric assessment and management units in the care of the frail elderly cancer patient. J Gerontol A Biol Sci Med Sci 2005; 60: 798-803 [PMID: 15983186 DOI: 10.1093/gerona/60.6.798]

Rubinstein LZ. Evolving models of comprehensive geriatric assessment. J Am Med Dir Assoc 2015; 16: 446-447 [PMID: 25843620 DOI: 10.1016/j.jamda.2015.03.012]

Overcash JA, Beckstead J, Extermann M, Cobb S. The abbreviated geriatric assessment
stage III colon cancer diagnosed after age 75 years. 2012; 2624-2634 [PMID: 22665536], Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, [PMID: 22250183 DOI: 10.1093/annonc/mdt577].

Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol 2012; 13: e437-e444 [PMID: 23026829 DOI: 10.1016/S1470-2045(12)70259-0].

Mobile SG, Dale W, Somerfield MR, Hurria A. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology Summary. J Oncol Pract 2018; 14: 442-446 [PMID: 29972846 DOI: 10.1200/JOP.18.00180].

Decoster L, Van Puyvelde K, Mohile S, Wedding U, Basso U, Colloca G, Rostoft S, Overcash J, Wilders H, Steer C, Kimmick G, Kanavanavan R, Luciani A, Terret C, Hurria A, Kenis C, Audrisio R, Extermann M. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. Ann Oncol 2015; 26: 288-300 [PMID: 24936581 DOI: 10.1093/annonc/mdu210].

Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, Seitz JF, Francini G. A pooled analysis of adjuvant chemotherapy for resected colon cancer patients. N Engl J Med 2001; 345: 1091-1097 [PMID: 11596588 DOI: 10.1056/NEJMoa010957].

O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ Jr, Ehrlichman C, Shepherd L, Moertel CG, Karch WJ, Pazzur R, Weand HS, Rubini J, Vukov AM, Donohue JH, Krock JE, Figueroa A. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16: 295-300 [PMID: 9440756 DOI: 10.1200/JCO.1998.16.2.295].

Francini G, Petrioli R, Lorenzini I, Mancini S, Armenio S, Tanzi G, Marsili S, Aquino A, Marzocca G, Civitelli S. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994; 106: 899-906 [PMID: 8149395 DOI: 10.1016/0016-5085(94)90748-x].

Zuckerman IH, Rapp T, Onunkwugha E, Davidoff A, Choti MA, Gardner J, Seal B, Mullins CD. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with stage III colon cancer. J Am Geriatr Soc 2009; 57: 1403-1410 [PMID: 19563521 DOI: 10.1111/j.1532-5415.2009.02355.x].

Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 2005; 294: 2703-2711 [PMID: 16333005 DOI: 10.1001/jama.294.21.2703].

Neugut AI, Matsaru M, Wang X, McBride R, Jacobson JS, Tsai WY, Granr VR, Hershman DL. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 2006; 24: 2368-2375 [PMID: 16618945 DOI: 10.1200/JCO.2005.04.5001].

Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Billingsley K, Barlow W. Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst 2006; 98: 610-619 [PMID: 16670386 DOI: 10.1093/jnci/dji159].

Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, Bugat R, Burger U, Garin A, Graeven U, McKenzie J, Maroun J, Marshall J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schils RK. Capecitabine Colorectal Cancer Study Group. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566-575 [PMID: 12057007 DOI: 10.1093/annonc/mda809].

Yoshitani S, Takashima S. Efficacy of postoperative UFT (Tegafur/Uracil) plus PSK therapies in elderly patients with resected colorectal cancer. Cancer Biother Radiopharm 2004; 29: 35-40 [PMID: 15127680 DOI: 10.1089/cbr.2004.29.35].

Meyers BM, Cosby R, Querechy F, Jonker D. Adjuvant Chemotherapy for Stage II and III Colon Cancer Following Complete Resection: A Cancer Care Ontario Systematic Review. Clin Oncol (R Coll Radiol) 2017; 29: 459-465 [PMID: 28341242 DOI: 10.1016/j.clon.2017.03.001].

Hallier DG, O'Connell MJ, Cartwright TH, Twelves CJ, McKenna EF, Sun W, Saif MW, Lee S, Yothers G, Schmoll HJ. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. Ann Oncol 2015; 26: 713-724 [PMID: 25598334 DOI: 10.1093/annonc/mdu061].

Batra A, Cheung WY. Role of real-world evidence in informing cancer care: lessons from colorectal cancer. Curr Oncol 2019; 26: S53-S56 [PMID: 31819710 DOI: 10.3747/co.26.5625].

Green SL, Dawe DE, Nugent Z, Cheung WY, Craykowski PM. The use of chemotherapy in older patients with stage II and III colon cancer: Variation by age and era of diagnosis. J Geriatr Oncol 2019; 10: 132-137 [PMID: 30104156 DOI: 10.1016/j.jgo.2018.07.012].

Lund JL, Stürmer T, Harlan LC, Sanoff HK, Sandler RS, Brookhart MA, Warren JL. Identifying specific chemotherapeutic agents in Medicare data: a validation study. Med Care 2013; 51: e27-e34 [PMID: 22800337 DOI: 10.1097/MLR.0b013e31823ab600].

Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meierhenry JA, Stürmer T, Fine JP, Weeks J, Noland J, Kahn KL, Schymura MJ, Schrag D. Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst 2012; 104: 211-227 [PMID: 22266473 DOI: 10.1093/jnci/djr524].

Sanoff HK, Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Noland J, Kahn KL, Schymura MJ, Schrag D. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol 2012; 30: 2624-2634 [PMID: 22665536].
Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zallig LL, Goldberg RM, Schymura MJ, Schrag D. Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. *Cancer* 2012; 118: 4309-4320 [PMID: 22294436 DOI: 10.1002/cncr.27422]

O'Connor ES, Greenblatt DY, LoConte NK, Gangnon RE, Liou JI, Heise CP, Smith MA. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. *J Clin Oncol* 2011; 29: 3381-3388 [PMID: 21788561 DOI: 10.1200/JCO.2010.34.3426]

Papamichael D, Audisio RA, Glimelius B, de Gramont A, Glynne-Jones R, Haller D, Köhne CH, Rostoft S, Lemmens V, Mitry E, Rutten H, Sargent D, Sastre J, Seymour M, Starling N, Van Cutsem E, Aapro M. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. *Ann Oncol* 2015; 26: 463-476 [PMID: 25015334 DOI: 10.1093/annonc/mdu255]
